Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Medical cannabis as an alternative therapeutics for Parkinsons disease: Systematic review (2020) |
Auteurs : | Anastasia Bougea ; Christos Koros ; Athina-Maria Simitsi ; et al. |
Type de document : | Article |
Dans : | Complementary Therapies in Clinical Practice (Vol. 39, May 2020) |
Article en page(s) : | 9p. |
Note générale : | https://doi.org/10.1016/j.ctcp.2020.101154 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Essai clinique ; Législation ; Marijuana médicale ; Thérapies complémentaires |
Résumé : |
Objectives
1) to evaluate the efficacy of medical cannabinoids (MC) by appraising the quality of evidence from clinical studies 2) to explore the factors hampering the MC use in clinical practice of Parkinson's disease (PD). Methods We performed a systematic review through various databases. The quality of 14 studies was assessed by Cochrane risk bias (5 randomized controlled trials- RCT) and Newcastle-Ottawa scale (9 uncontrolled studies). Results The positive effects on motor (5 studies) and non-motor symptoms (4 studies) described in uncontrolled studies have not been confirmed by the few and small RCTs. Only one RCT found a reduction of levodopa-induced dyskinesias, another a reduction in anxiety and tremor amplitude in an anxiogenic situation, while the remaining three without effect on motor/non-motor symptoms. Physical and psychological symptoms are among the most common side effects. Conclusions There is insufficient evidence to reform international legislation regarding cannabis use in PD practice. |
Disponible en ligne : | Non |
Exemplaires (1)
Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|
Périodique papier | Woluwe | Espace revues | Consultation sur place uniquement Exclu du prêt |